- Preview Available
- Scholarly Journal
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
Blood Cancer Journal; London Vol. 14, Iss. 1, (Dec 2024): 216.
DOI:10.1038/s41408-024-01202-8
This is a limited preview of the full PDF
Try and log in through your library or institution to see if they have access.